NEWS HIGHLIGHTSMedia Articles Related to Opana (Oxymorphone)
FDA Asks Maker of Opioid Painkiller Opana ER to Pull Drug From Market
Source: MedicineNet oxycodone Specialty [2017.06.09]
Title: FDA Asks Maker of Opioid Painkiller Opana ER to Pull Drug From Market
Category: Health News
Created: 6/9/2017 12:00:00 AM
Last Editorial Review: 6/9/2017 12:00:00 AM
A Look Back: Abandoned Painkiller Makes a Comeback
Source: MedPage Today Emergency Medicine [2017.06.09]
(MedPage Today) -- Backstory on Opana ER, which the FDA now wants off the market
Medical News Today: Tailbone pain: Causes, diagnosis, and relief
Source: Featured Health News from Medical News Today [2017.06.24]
Pain in the coccyx, or tailbone, can appear for a number of reasons, including injury, childbirth, and degeneration. Learn more in this article.
Tailbone pain: Causes, diagnosis, and relief
Source: Body Aches News From Medical News Today [2017.06.24]
Pain in the coccyx, or tailbone, can appear for a number of reasons, including injury, childbirth, and degeneration. Learn more in this article.
One in 10 in Rheumatic Pain Switch Back From a Biosimilar
Source: Medscape Orthopaedics Headlines [2017.06.22]
As more and more patients with rheumatic disease switch from a biologic to a biosimilar, a new study assesses how many switch back to the originator.
Medscape Medical News
Published Studies Related to Opana (Oxymorphone)
Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. [2011.05]
OBJECTIVE: To compare the subjective effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSIONS: At equianalgesic doses, single oral intact OM-ER produced lower positive, negative, and balance subjective effects than OC-CR, indicating that analgesic potency may not necessarily be reflected in subjective/objective effects.
Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. [2010.11]
BACKGROUND: Opioids provide effective pain control, yet have risks including adverse events (AEs) (e.g., constipation, nausea/vomiting, sedation) and cognitive/psychomotor effects. OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR)... CONCLUSION: Single oral intact low and high doses of OM-ER produced less cognitive and psychomotor impairment plus less sedation than equianalgesic OC-CR in this exploratory study. ClinicalTrials.gov registration NCT00955110.
Long-term tolerability and effectiveness of oxymorphone extended release in patients with cancer. [2010.05]
OBJECTIVE: To evaluate the long-term safety, tolerability, and effectiveness of oxymorphone extended release (ER) in patients with cancer-related pain... CONCLUSIONS: In these patients with pain related to cancer, oxymorphone ER was generally well tolerated and provided stable long-term pain control.
The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
OBJECTIVE: In controlled trials of analgesics, the primary outcome variable is most often a measure of global pain intensity. However, because pain is associated with a variety of pain sensations, the effects of analgesic treatments on different sensations could go undetected if specific pain qualities are not assessed...
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
OBJECTIVE: This study assessed the potential effects of age, sex, and prior opioid use on the response to oxymorphone extended release (ER) in patients with moderate to severe chronic low back pain... CONCLUSION: In the enriched population of patients who successfully titrated to oxymorphone ER, oxymorphone ER was effective and generally well tolerated, independent of patients' age, sex, or previous opioid use.
Clinical Trials Related to Opana (Oxymorphone)
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions [Completed]
The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone
hydrochloride extended-release tablets (Sandoz) with Opana extended release oxymorphone
hydrochloride tablets.
Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects [Terminated]
Patients will convert from current opioid to Oxymorphone ER and undergo titration. During
the Titration Period, subjects will receive daily oxymorphone Extended Release tablets(s)
every 12 hours. Dosing adjustments will be based on the review of the subject's pain
scores. Oxymorphone IR 5 mg will be provided to be used as supplemental "breakthrough" pain
medication (as needed). Titration Period will end when the fixed dose of study medication
is tolerated and the subject achieves adequate analgesia. Subjects will then proceed to the
open-label 3-month maintenance period on the fixed dose of study medication established
during the Titration Period.
Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin) [Completed]
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions [Completed]
The purpose of this study is to demonstrate the relative bioequivalence of oxymorphone
hydrochloride extended release tablets (Sandoz) with Opana extended release oxymorphone
hydrochloride tablets.
Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions [Completed]
The objective of this study was to prove the bioequivalence of Oxymorphone Hydrochloride 10
mg Tablets under fasting conditions
Reports of Suspected Opana (Oxymorphone) Side Effects
Drug Abuse (22),
Drug Ineffective (20),
Insomnia (19),
Weight Decreased (15),
Drug Dependence (15),
Respiratory Depression (12),
Agitation (11),
Tinnitus (11),
Intentional Drug Misuse (11),
Pain (10), more >>
|
